Kodiak Sciences (KOD) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
Three late-stage retinal programs advanced; no product revenue to date and operating losses continue.
Zenkuda and KSI-501 met DAYBREAK one-year visual-acuity endpoints; a three-indication Zenkuda BLA is planned for Q4 2026.
KSI-101 PEAK first-cohort topline results remain on track for December 2026; substantial doubt exists about going-concern status.
Financial highlights
Q3 2026 R&D expense was $58.3M vs. $50.5M YoY; G&A was $8.8M vs. $11.9M, reflecting a non-cash lease-termination gain.
Q3 net loss was $66.2M, or $1.05/share, vs. $61.5M, or $1.16/share; nine-month net loss was $190.0M vs. $173.2M.
Nine-month operating expenses rose to $193.7M from $176.9M; net cash used in operations was $130.1M vs. $96.6M.
Cash and cash equivalents were $88.7M at September 30, 2026, down from $209.9M at December 31, 2025; cash, cash equivalents and restricted cash totaled $92.6M.
Accumulated deficit was $1.75B and stockholders’ equity was $12.6M at September 30, 2026.
Outlook and guidance
Zenkuda three-indication BLA for wet AMD, diabetic retinopathy and retinal vein occlusion planned for Q4 2026.
KSI-101 PEAK first-cohort topline results expected in December 2026; second-cohort enrollment across PEAK and PINNACLE expected to finish in Q4 2026, with data anticipated in Q2 2027.
KSI-101 BLA filing planned for Q2 2027, conditional on successful PEAK and PINNACLE results.
Cash may not cover operating and capital needs for the 12 months following the report; additional financing is planned, though cash was expected to support current and planned operations into 2027.
Latest events from Kodiak Sciences
- Tarcocimab advances toward filing as KSI-101’s pivotal data approach.KOD
UBS Global Biopharma Conference 2026 - Zenkuda’s BLA, KSI-101’s PEAK 1 readout and accelerating KSI-501 trials define the near-term milestones.KOD
Jefferies Global Healthcare Conference - Both drugs matched aflibercept efficacy, enabling 6-month dosing for most patients.KOD
Study result - Net loss hit $123.8M in H1 2026; cash supports operations into 2027, but funding gap remains.KOD
Q2 2026 - Late-stage retinal therapies advance toward key data and BLA filings, targeting approvals by 2027.KOD
Jefferies Global Healthcare Conference 2026 - Q1 2026 saw a $58.2M net loss, strong Phase 3 data, and pivotal trials with funding needs ahead.KOD
Q1 2026 - Virtual meeting to elect directors, approve pay, and ratify auditor, with board support.KOD
Proxy filing - Shareholders will vote on directors, executive pay, and auditor, with a focus on performance and ESG.KOD
Proxy filing - Pivotal retinal trials advance with improved formulations and strong financial runway.KOD
Goldman Sachs 45th Annual Global Healthcare Conference